Polymnia Louka
Stable Sulforaphane Targets the Early Stages of Osteoclast Formation to Engender a Lasting Functional Blockade of Osteoclastogenesis
Louka, Polymnia; Orriss, Isabel R.; Pitsillides, Andrew A.
Authors
Isabel R. Orriss
Andrew A. Pitsillides
Abstract
Sulforaphane, the native but unstable form of SFX-01, is an antioxidant that activates the NRF2 and inhibits the NF-KB pathways to achieve its actions. Resolving the mechanism(s) by which SFX-01 serves to control the various osteoclastogenic stages may expose pathways that could be explored for therapeutic use. Here we seek to identify the stage of osteoclastogenesis targeted by SFX-01 and explore whether, like SFN, it exerts its actions via the NRF2 and NF-KB pathways. Osteoclasts generated from the bone marrow (BM) of mice were cultured with SFX-01 at different timepoints to examine each phase of osteoclastogenesis separately. This showed that SFX-01 exerted actions throughout the process of osteoclastogenesis, but had its largest effects in the early osteoclast precursor differentiation stage. Thus, treatment with SFX-01 for the duration of culture, for the initial 3 days differentiation or for as little as the first 24 h was sufficient for effective inhibition. This aligned with data suggesting that SFX-01 reduced DC-STAMP levels, osteoclast nuclear number and modified cytoskeletal architecture. Pharmacological regulation of the NRF2 pathways, via selective inhibitors/activators, supported the anti-osteoclastogenic roles of an SFX-01-mediated by NRF2 activation, as well as the need for tight NF-KB pathway regulation in osteoclast formation/function.
Citation
Louka, P., Orriss, I. R., & Pitsillides, A. A. (2024). Stable Sulforaphane Targets the Early Stages of Osteoclast Formation to Engender a Lasting Functional Blockade of Osteoclastogenesis. Cells, 13(2), https://doi.org/10.3390/cells13020165
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 9, 2024 |
Online Publication Date | Jan 16, 2024 |
Publication Date | 2024 |
Deposit Date | May 7, 2024 |
Publicly Available Date | May 7, 2024 |
Print ISSN | 2073-4409 |
Electronic ISSN | 2073-4409 |
Publisher | MDPI |
Peer Reviewed | Peer Reviewed |
Volume | 13 |
Issue | 2 |
DOI | https://doi.org/10.3390/cells13020165 |
Keywords | sulforaphane; osteoclasts; osteoclastogenesis; NRF2 and NF-KB |
Files
Stable Sulforaphane Targets the Early Stages of Osteoclast Formation to Engender a Lasting Functional Blockade of Osteoclastogenesis
(5.5 Mb)
PDF
Licence
http://creativecommons.org/licenses/by/4.0/
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
Version
VoR
You might also like
Expression of semaphorin-3A in the joint and role in osteoarthritis
(2024)
Journal Article
Bone marrow lesions: plugging the holes in our knowledge using animal models
(2023)
Journal Article
Downloadable Citations
About RVC Repository
Administrator e-mail: publicationsrepos@rvc.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search